PRECLINICAL AND CLINICAL STRATEGIES FOR DEVELOPMENT OF TELOMERASE ANDTELOMERE INHIBITORS

Citation
S. Sharma et al., PRECLINICAL AND CLINICAL STRATEGIES FOR DEVELOPMENT OF TELOMERASE ANDTELOMERE INHIBITORS, Annals of oncology, 8(11), 1997, pp. 1063-1074
Citations number
116
Language
INGLESE
art.tipo
Review
Journal title
ISSN journal
0923-7534
Volume
8
Issue
11
Year of publication
1997
Pages
1063 - 1074
Database
ISI
SICI code
0923-7534(1997)8:11<1063:PACSFD>2.0.ZU;2-J
Abstract
Background: Telomerase is an important enzyme whose activity has been convincingly demonstrated in humans recently. It is required for maint enance of ends of chromosomes (telomeres) during cell division. Since its presence has been selectively demonstrated in dividing cells inclu ding tumor cells, it has generated considerable excitement as a potent ial anticancer strategy. Design: In this article, we review the curren t relevant biology of the enzyme, the challenges encountered in the pr eclinical phase of target development and the current efforts that foc us on telomeres and telomerase as therapeutic targets. We also specula te on the potential toxicities and mechanisms of resistance that may b e encountered during use of such therapies.